Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Nebulized Placebo Solution Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

NCT02709109
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-371 + HS, Hypertonic saline, Placebo, Orkambi, VX-371
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Little Rock, Arkansas • Oakland, California • Gainesville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 6, 2026, 1:18 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Albuterol, Normal Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional

A 12-Week Study in Adult Subjects With Asthma

NCT01516086
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate (FP)
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rock Hill, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional

12-Week Study in Adult Subjects With Asthma

NCT01516073
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate
Drug
Lead sponsor
Dey
Industry
Eligibility
18 Years to 60 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nebulized Hypertonic Saline for Mechanically Ventilated Children

NCT01945944
View directory record Official record
Conditions
Respiratory Failure
Interventions
Hypertonic saline (3%), Placebo (0.9% saline)
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
Up to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022
View directory record Official record
Conditions
Healthy
Interventions
Clinical Center Reference Endotoxin (CCRE), Normal saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations

NCT01988779
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
oral levofloxacin, nebulized levofloxacin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU)

NCT01356147
View directory record Official record
Conditions
Pulmonary Infections
Interventions
Dornase alfa, Placebo
Drug
Lead sponsor
Georgetown University
Other
Eligibility
7 Days to 4 Months
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Sep 6, 2026, 1:18 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of Ipratropium Bromide on EILO

NCT07394036
View directory record Official record
Conditions
Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions
Ipratropium Bromide, Normal Saline (Placebo)
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
8 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Prosper, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 6, 2026, 1:18 PM EDT
Not yet recruiting Phase 4 Interventional

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

NCT07721922
View directory record Official record
Conditions
COPD Exacerbation
Interventions
Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline), Albuterol sulfate, Ipratropium Bromide
Drug · Other
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
40 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Not applicable Interventional Results available

Assessment of Arformoterol for Chronic Obstructive Pulmonary Disease (COPD) Using Hyperpolarized 3He MRI

NCT00846287
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized Helium-3, Placebo, Aformoterol
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
50 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 6, 2026, 1:18 PM EDT
Not listed Early Phase 1 Interventional

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

NCT00536952
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pulmozyme, Placebo, Radiation Therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

NCT00179998
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Recombinant Human DNase (Pulmozyme), Placebos
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Month to 30 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Sep 6, 2026, 1:18 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 6, 2026, 1:18 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of NAC on Lung Function and CT Mucus Score

NCT03822637
View directory record Official record
Conditions
Asthma
Interventions
n-acetylcystine + albuterol, 0.9% saline + albuterol
Combination Product
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 4 Interventional Results available

Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD

NCT00754546
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Arformoterol tartrate, Placebo: Normal Saline, Treadmill Exercise, Cycle Exercise
Drug · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 28, 2013 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Early Phase 1 Interventional

Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit

NCT01878643
View directory record Official record
Conditions
Respiratory Infection, Bacterial Resistance, Respiratory Failure
Interventions
vancomycin or gentamicin, Placebo
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction

NCT02262078
View directory record Official record
Conditions
Heart Failure
Interventions
Sodium Nitrite Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04535986
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
763 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Peoria, Arizona • Tempe, Arizona • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers

NCT00814645
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sodium Nitrite Inhalation Solution, Placebo and AIR001 Inhalation Solution (Expansion arm)
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 6, 2026, 1:18 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dupilumab in Children With Uncontrolled Asthma

NCT02948959
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo, Asthma Controller Therapies, Asthma Reliever Therapies
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years to 11 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 6, 2026, 1:18 PM EDT